Refresh your memory of 4 CGM systems that received FDA-approval in 2018. Each one offers innovative features to help enhance diabetes care.
In 2018, the FDA issued approvals for several continuous glucose monitors (CGMs), and an expanded indication for a closed-loop artificial pancreas system. Since then, these systems have been rolled out and are currently being marketed in the US. This short slideshow offers compact summaries on 4 of these products which all offer innovative features like extended sensor wear-time, elimination of daily finger stick calibration, and integration with Siri and Google Fit apps.
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
October 27th 2025After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.